More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by...
More on Watson Pharma (WPI +2.1%) Q1: Net income +21% to $54.8M, with earnings boosted by Watson's generic versions of the Lipitor cholesterol drug and Lovenox blood thinner, and a rise in international sales. 2012 guidance: adjusted EPS $5.55-$5.80 and revenue $5.5B vs. consensus of $5.80 and $5.5B.
From other sites
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
at CNBC.com (Feb 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs